高级检索
    评价者: 宋玉琴, 文献合成者: 蔡绮纯. 去化疗时代的开启: 利妥昔单抗联合来那度胺一线治疗套细胞淋巴瘤[J]. 循证医学, 2016, 16(2): 80-82. DOI: 10.12019/j.issn.1671-5144.2016.02.007
    引用本文: 评价者: 宋玉琴, 文献合成者: 蔡绮纯. 去化疗时代的开启: 利妥昔单抗联合来那度胺一线治疗套细胞淋巴瘤[J]. 循证医学, 2016, 16(2): 80-82. DOI: 10.12019/j.issn.1671-5144.2016.02.007
    shu
    Reviewer: SONG Yu-qin, Literature Co-worker: CAI Qi-chun. The Beginning of Non-Chemotherapy Era: Lenalidomide plus Rituximab as First-Line Therapy for Mantle-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 80-82. DOI: 10.12019/j.issn.1671-5144.2016.02.007
    Citation: Reviewer: SONG Yu-qin, Literature Co-worker: CAI Qi-chun. The Beginning of Non-Chemotherapy Era: Lenalidomide plus Rituximab as First-Line Therapy for Mantle-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 80-82. DOI: 10.12019/j.issn.1671-5144.2016.02.007
    shu

    去化疗时代的开启: 利妥昔单抗联合来那度胺一线治疗套细胞淋巴瘤

    The Beginning of Non-Chemotherapy Era: Lenalidomide plus Rituximab as First-Line Therapy for Mantle-Cell Lymphoma

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回